BridgeBio Oncology Therapeutics (BBOT) Payables (2023 - 2026)
BridgeBio Oncology Therapeutics (BBOT) posted Payables of $12.8 million for Q1 2026, up 571.17% sequentially from $1.9 million in Q4 2025, and up 14588.64% YoY from N/an in Q1 2025.
BridgeBio Oncology Therapeutics (BBOT) Payables (2023 - 2026) Analysis & Trends
BridgeBio Oncology Therapeutics has reported Payables for 4 years, with the latest figure at $12.8 million in Q1 2026.
- Quarterly Payables rose 14588.64% year-over-year to $12.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.8 million (up 14588.64% YoY) and the FY2025 annual result came in at $1.9 million, down 46.36% from the prior year.
- Payables climbed to $12.8 million in Q1 2026 per BBOT's latest filing, from $1.9 million in the prior quarter.
- Over five years, Payables peaked at $12.8 million in Q1 2026 and troughed at $9687.0 in Q1 2024.
- A 4-year average of $3.2 million and a median of $2.3 million in 2025 frame the typical range for Payables.
- The sharpest annual moves came in 2025 and 2026: Payables tumbled 46.36% in 2025, then surged 14588.64% in 2026.
- Over 4 years, Payables stood at $70095.0 in 2023, then jumped by 4974.54% to $3.6 million in 2024, then sank by 46.36% to $1.9 million in 2025, then surged by 571.17% to $12.8 million in 2026.
- According to Business Quant data, Payables over the past three periods registered $12.8 million, $1.9 million, and $4.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | BridgeBio Oncology Therapeutics | 726.38 Mn | 500.67 Mn | - | 6.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.73 Mn |
| Mar 31, 2026 | 12.81 Mn |
| Dec 31, 2025 | 1.91 Mn |
| Sep 30, 2025 | 4.34 Mn |
| Jun 30, 2025 | 2.63 Mn |
| Mar 31, 2025 | 87,183.00 |
| Dec 31, 2024 | 3.56 Mn |
| Mar 31, 2024 | 9,687.00 |
| Dec 31, 2023 | 70,095.00 |